Stem Cell Research Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stem Cell Research

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	10/21/2008 4:13:45 AM
	of 495

Stem cell trial nearly a go? the-scientist.com Posted by Andrea Gawrylewski The first clinical trial treatment based on embryonic stem cells may soon get the go ahead. In May, the Food and Drug Administration placed a hold on a clinical trial application submitted by Geron Corporation, a California-based biotech. The company submitted a 22,500-page Investigational New Drug application to the FDA for an embryonic stem cell-derived compound -- called GRNOPC1 -- to treat spinal cord injury. Geron president and CEO, Tom Okarma, said at the New York Stem Cell Foundation conference at Rockefeller University on Wednesday (October 15) that the company has had to "educate" the FDA on all the procedures used to grow, quantify, and characterize their stem cell populations. He added that there is no evidence of political pressures behind the hold, and he thinks the FDA did the right thing to hold the trial, in order to get a grasp on the science and ensure safety. But the FDA is nearing the end of its review process and may lift the hold and allow clinical trials to commence within the next three months, Okarma told The Scientist. "We've got our arms wrapped around it," he added. "It's been a long education process."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next